- Home
- ABEO vs NSTR Comparison
ABEO vs NSTR Comparison
Compare ABEO & NSTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$4.35
N/A
Current Price
$3.20
Company Overview
Basic Information| Metric | ABEO | NSTR |
|---|---|---|
| Founded | 1974 | 2018 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.5M | 264.3M |
| IPO Year | 2005 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ABEO | NSTR |
|---|---|---|
| Price | $4.35 | $3.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $18.88 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 107.8K |
| Earning Date | 11-11-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $804.33 | N/A |
| Revenue Next Year | $119.68 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $2.49 |
| 52 Week High | $7.65 | $4.14 |
Technical Indicators
Market Signals| Indicator | ABEO | NSTR |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 50.74 |
| Support Level | $4.27 | $2.80 |
| Resistance Level | $5.91 | $3.97 |
| Average True Range (ATR) | 0.23 | 0.72 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 10.83 | 43.75 |
Price Performance
Historical Comparison ABEO
NSTR
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.